Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc
Bullboard Posts
User Avatar Image
(4)
•••
Comment by jordon3on Mar 21, 2019 10:05am
93 Views
Post# 29516255

RE:time for a PR

RE:time for a PRNamlak...definitely time for a NR.  as this article states last year. " Success for aducanumab could be favorable for PMN310 as it validates the target for toxic ABO's and will bring substantial attention to the ProMis program."     Looks like the news today has done the opposite.


Zacks Small Cap Research - PMN.TO: In Alzheimer's, It's the ...


https://scr.zacks.com/News/Press-Releases/Press-Release-Details/.../default.aspx
May 31, 2018 - ProMIS' approach is highly selective for these specific AβOs thereby avoiding ... vTv's azeliragon and the closure of Pfizer's neuroscience division. .... Shifting to a more efficient immunoglobulin backbone IgG4 would also confer benefits ... Success for Biogen's drug will be a positive for ProMIS and PMN310 ...
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities